Clinical Subscriber Growth and High Gross Margins Highlight WW’s Q1 2026 Performance
Market Chameleon (Thu, 7-May 9:43 AM)
WW Puts Deleveraging First as Up to $40 Million Targeted for Debt Reduction—Financial Guidance Reaffirmed
Market Chameleon (Mon, 27-Apr 11:44 AM)
WW Expands Med+ Offering With New Oral GLP-1 Treatment—Access to Foundayo Signals Broader Market Opportunity
Market Chameleon (Thu, 9-Apr 9:36 AM)
